DS86760016 is a new leucyl-tRNA-synthetase inhibitor in the preclinical development stage. DS86760016 showed potent activity against extended spectrum multidrug-resistant Pseudomonas aeruginosa isolated from clinical samples and in-vitro biofilms. In a murine catheter associated urinary tract infection model, DS86760016 treatment resulted in significant eradication of P. aeruginosa counts from kidney, bladder and catheter without developing drug-resistance. Our data suggest that DS86760016 has the potential to act as a new drug for the treatment of Pseudomonas infections.
http://bit.ly/2W81avP
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου